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Abstract: The cost burden of COPD is substantial for patients and families, payers, and
society as a whole. Smoking has been known for decades to be the leading cause of the
disease. Numerous studies have been completed to address the cost-effectiveness of programs
created to aid smokers in their efforts to quit. Because several assumptions must be made in
order to conduct such a study, and because differences in study design are numerous,
comparison of data is difficult. However, studies have consistently shown that regardless of
the perspective from which the study was completed, or the methods used to help smokers
abstain, the interventions are cost-effective. Although no study has been conducted specifically
to assess the cost-effectiveness of smoking cessation interventions as they relate directly to
patients with COPD, based on current data it can be concluded that smoking cessation programs
are cost-effective for this population.
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Introduction
Within the next 20 years, it is anticipated that COPD will rank fifth for overall causes
of disability worldwide (Murray and Lopez 1996). Year 2000 statistics rank COPD
as the fourth most common cause of death in the US (Minino and Smith 2001).
When considering smoking burden in the mortality rankings, COPD rises from fourth
to third with greater than 25% of all money spent on smoking-related illness consumed
as a result (Zaher et al 2004). From a global perspective, COPD is first on the list for
worldwide deaths related to smoking. The medical community has been aware of the
connection between the use of tobacco and the incidence of COPD for decades. It is
estimated that between 1 in 10 and 1 in 20 long-term smokers will develop clinical
disease (Strassels 1999). Perhaps even more striking than that, however, is the fact
that in comparison with non-smokers, those who abuse tobacco exhibit a mortality
rate 12–13 times higher (American Lung Association 2005). Although COPD ranks
behind coronary heart disease and stroke when comparing disability-adjusted life
years, it has the greatest smoking-related influence since the disease may begin to
have an impact on the life and health of a smoker several decades before death. The
average smoker loses 8 years of life, and 25% will die before the age of 69 years
(Secretary of State for Health and Secretaries of State for Scotland, Wales, and
Northern Ireland 1998).
Economic impact of COPD
Establishing the cost burden of COPD is a daunting task. In order to create the most
accurate picture, both direct costs (medications and oxygen, services through health-
care providers, inpatient stays, institutional care, diagnostic testing, and visits to the
emergency room) and indirect costs (lost wages due to illness that encompass both
patients and caregivers, decreased productivity on the job, and travel) must be taken
into account. Clearly the former category is the easiest to quantify. Possible variations
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such as inaccuracy of diagnostic coding and methods used
to estimate future earnings further cloud the issue.
The costs associated with COPD are substantial, and data
show that overall healthcare expenditures for patients with
COPD are nearly double that of those without (Mapel et al
2000). In 1993 US dollars, COPD was found to cost triple
that of asthma on a per capita basis at an average of $1522
annually (Sullivan et al 2000). A study examining the amount
of money spent for patients under Medicare found costs to
be nearly 2.5 times higher for beneficiaries with COPD than
those without ($8482 vs $3511 per capita respectively)
(Grasso et al 1998). A study designed to estimate the annual
direct medical costs of the disease from a societal perspective
(1996 dollars) found that $14.5 billion were expected to be
spent on patients with chronic bronchitis or emphysema
(Wilson et al 2000). Hospitalizations and medication use
accounted for the majority of these projected costs. Indirect
costs were not estimated in this study, making those
predictions a significant underestimation of the true cost of
the disease. Another study that prospectively followed
patients at multiple centers for a full year to determine the
direct cost of COPD was published in 2003 (Miravitlles et
al 2003). Medications and oxygen, costs of physician visits
and visits to the emergency room for exacerbations,
hospitalizations, admissions to an intensive care unit, and
procedure–test costs were included in the data analysis. The
mean cost of a single exacerbation was found to be $159,
and the global direct yearly per-patient cost was $1876.
These figures are again bound to be underestimations
because of the exclusion of indirect cost measurement.
Optimization of the care of the COPD patient typically
costs a substantial amount of money, and cost-minimization
strategies may be in direct opposition to that goal (Sullivan
et al 2000). Those individuals charged with deciding policy
must take several factors into consideration including the
burden of the disease (epidemiology as well as cost), the
environment of the setting in question, and the cost-
effectiveness of available interventions. Though both the
young and the old abuse tobacco, the disease burden is
substantially higher in patients over the age of 65 years
(National Heart, Lung, and Blood Institute 2000). COPD is
relatively rare in persons younger than middle-age (Ward
et al 2000). This is an important factor to consider when
looking at any intervention that affects the outcomes of
patients with COPD since preserved years of life and the
quality of those years are primary markers of cost-
effectiveness. Disability-adjusted life years, mortality rates,
and rates of hospitalization for COPD are greater than are
those for coronary heart disease, stroke, and lung cancer
(Zaher et al 2004). When examining cost-effectiveness, it
is necessary to take all future costs of treatment and disease
into account as COPD remains a progressive and incurable
disease that will be present for the lifetime of the patient
(Ramsey and Sullivan 2003).
Cost-effectiveness analysis
Determining the cost-effectiveness (CE) of an intervention
is far from simple. As stated previously, both direct and
indirect costs must be included in an analysis in order to
consider it complete. However, most CE analyses consider
only direct costs. The principal result of a CE analysis is
the incremental CE ratio. This ratio takes the amount by
which the cost of one intervention exceeds another (the
incremental cost), and divides that figure by the amount of
money that the use of the intervention in question exceeds
the outcome expected by the alternative (the incremental
effectiveness) (Garber 1996).
The United States Panel on Cost-effectiveness in Health
and Medicine, formed by the United States Public Health
Service (USPHS), recommended that certain standards be
met by investigators of CE analyses (Ubel et al 2000). A
cost utility analysis is designated the gold standard. Such
an analysis estimates the number of quality adjusted life
years (QALYs) produced when a particular amount of
money is used to fund a specific intervention (Boyd et al
1990). QALYs take into account the years that are affected
by an illness and weights them of lower value than those
during which a patient enjoys good health. A value of 0 is
designated for years during which the patient’s quality of
life is no better than death, and a value of 1 implies perfect
health and the best possible quality of life (Garber 1996).
The point at which an intervention stops being cost-effective
has been defined in the medical literature as between $20 000
and $50 000 per QALY (Warner 1997; Tengs and Wallace
2000). In the UK, the National Institute for Clinical
Excellence has set the benchmark for CE at £20 000 per
QALY (Godfrey et al 2005). QALYs are the preferred
outcome measure as suggested by the USPHS.
CE analyses can be performed from multiple
perspectives including those of society at large (program
cost), an insurer, a patient, or an employer. Because the
process of CE analysis is neutral politically and
economically, public debate about where money should be
spent will continue. Though the most appropriate perspective
is still being deliberated, the USPHS stipulates that public
utility estimates should be the basis for measurements ofInternational Journal of COPD 2006:1(3) 281
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the CE of a given intervention (Ubel et al 2000). The
argument for this perspective is that CE analysis exists as a
tool to determine how scarce resources belonging to a society
should be assigned. An individual patient is not shrouded
from self-interest, making bias in the assignment of CE a
possibility. However, the argument can be made that because
society as a whole is blind to the effects of a specific illness,
it cannot make informed decisions, and a bias against an
illness, particularly an illness such as COPD that is
sometimes designated a disease of self-infliction, may cloud
the issue. Additionally, society may not look at CE as an
issue solely of QALYs, but may favor patients who are
severely ill, meaning that fewer QALYs would be gained
through an intervention in comparison with interventions
aimed at those with a smaller disease burden. The possibility
also exists for the geriatric population to be viewed as less
valuable because they are felt to have already consumed
their resources (Ubel et al 2000). An employer may see the
cost of an intervention as excessive since workers may leave
the company, making another employer the beneficiary of
a person’s improved productivity before the break-even
point. Additionally, it has been hypothesized that programs
requiring no financial investment on the part of the patient
may attract those who are in reality not as motivated to quit,
and as such, the overall effectiveness of the program may
be diminished (Curry et al 1998).
Discounting is another recommended component of a
CE analysis. Simply put, a given amount of money today is
worth more than that same amount will be tomorrow.
Therefore, when estimating future value, a discount rate
should be applied. The amount is controversial, but the
USPHS recommends 3%. A sensitivity analysis is often
applied to data as well. Because there are large disparities
in economic data, it is sometimes necessary to use a “best
guess” estimate. All studies examining the CE of smoking
cessation require the investigators to employ some amount
of modeling (Godfrey et al 2005). For instance, most studies
considered long-term extend for a maximum of 1 year;
however, smokers may still relapse past that point in time.
Because there are limited data beyond 12 months, long-term
rates of abstinence from smoking must be estimated (Song
et al 2002). The point at which patients can be labeled
lifelong quitters has yet to be determined (Ockene et al
2000). Utilization of a sensitivity analysis determines the
likelihood that the conclusion of an intervention as cost-
effective will be upheld if uncertain values are higher or
lower than those used for the original calculations (Garber
1996).
A comparison of CE analyses examined the utilization
of the USPHS recommendations (Phillips and Chen 2002).
Though discounting was frequently employed, only 22%
of studies used the suggested rate of 3%. Less than 1 in 3
reported QALYs as a primary outcome measure. Incremental
ratios were used more frequently, but were not a component
of 17% of studies. The disparities among study design make
comparisons from one to another difficult at best. The
population studied and the methods used can significantly
change outcomes (Haxby and Baldwin 1996).
Cost-effectiveness of smoking-
cessation programs
There are currently no studies examining the CE of smoking
cessation as it relates directly to patients with COPD. The
difficulty with the administration of such a study is that
COPD does not exist in a vacuum. Because patients with
COPD tend to be older, there is frequent overlap with other
diseases. Many of these, such as coronary heart disease,
hypertension, and cancer to name but a few, have their own
link to smoking. Therefore, if QALYs are to be used as an
outcome measure, it is unlikely that the physiological burden
of one disease will be easily separated from that of another.
Additionally, the ultimate cause of mortality might be
identifiable, but the decline in health leading up to that point
may not be attributable to a single illness. The number of
years of life saved in studies where disease-specific mortality
is estimated is typically smaller than when smokers and
quitters are compared for overall mortality rates (Curry et
al 1998).
Multiple studies examining the CE of various smoking
cessation programs and reporting outcomes in terms of
QALYs saved, or more frequently total life-years saved
(LYS), have been published (Table 1). Six of these studies
were completed to examine overall program (societal) costs.
Of these, two reported both QALYs saved and LYS (Javitz
et al 2004a; Feenstra et al 2005). The remaining four
programs all reported outcome data for LYS alone (Wasley
et al 1997; Lennox et al 2001; Tomson et al 2004; Godfrey
et al 2005). Three of the studies were done from the
perspective of the payer, one reporting cost per QALY saved
(Tran et al 2002), and the other two reporting cost per LYS
(Curry et al 1998; Gilbert et al 2004). The final study
evaluated data from the perspective of an employer over
the lifetime of its workforce and reported findings as cost
per LYS (Warner et al 1996). These ten studies were very
different in design and perspective, and included costs. Most
of them included a sensitivity analysis of the data generated,International Journal of COPD 2006:1(3) 282
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and the majority took background quit rates and likely
relapse percentages into account. Despite the inconsistency
in study design among the ten, the programs were all deemed
cost-effective by the investigators both pre- and post-
sensitivity analysis completion.
Several other studies examining CE have been
completed, but did not report data per QALY saved or LYS.
One such study, an economic model of bupropion and a
work-site smoking cessation program, demonstrated the CE
of the intervention (Halpern et al 2000). A comparison of
Table 1 Summary of studies reporting cost of quality adjusted life years/life years saved through various smoking cessation
programs
Study Cost  Cost Study Criteria for Discount Background Cost 
perspective measurement design successful rate quit/relapse
quit rate
Javitz et al Program QALY/LYS 4 groups (2 7 day 3% 1.5%/37% a$512–$2047/QALY
(2004a) doses abstinence at $116–$3590 (post SA)/
bupropion, 12 months QALY
2 behavioral $528–$2194/LYS
interventions) $106–$4295 (post SA) /
LYS 
Feenstra et al Program QALY/LYS Dynamic Permanent 4% NA/NA €1100–€4900/QALY
(2005) computer quit €1400–€6200/LYS
simulation over
75-year time
horizon
Tran et al Payer QALY Pharmacist vs 12 months of 3% 3%/75% $450–$578
(2002) patient-directed  continued $141–$2258 (post SA)
abstinence
Warner et al Employer LYS Computer Permanent quit 3.5% 2.5%/85%  $894 (at age 85 years)
(1996) simulation
cumulative over
lifetime  
Wasley et al Program LYS Counseling with 12 month 5% 1%/35% $362–$4391
(1997) and without abstinence $379–$6364 (post SA)
nicotine
replacement
Curry et al Payer LYS 4 plans with 7 day 3% NA/NA $928–$1192
(1998) different abstinence
financial at 6 months
investment by
smokers
Lennox et al Program LYS Individualized vs 6-month quit 5% NA/NA £50–£122
(2001) standardized rate
letters sent to
participants
Gilbert et al Payer LYS Counseling Not specified 3% 2.5%/35% $1311–$9777
(2004) alone vs any of
5 pharmacological
interventions
with follow-up
counseling
Tomson et al Program LYS Free quitline in No use within 3-5% NA/NA $311–$401
(2004) Sweden over previous 7 days $311–$1607 (post SA)
2-year period
Godfrey et al Program LYS Summary of Abstinence at 3.5% 2%/65% £557–£811
(2005) cessation services 4 weeks £438–£2293 (post SA)
in England (Converted to
(coordinator 12 months)
survey)
aUS$
Abbreviations: LYS, life-years saved; NA, not available; QALY, quality adjusted life year; SA, sensitiviy analysis.International Journal of COPD 2006:1(3) 283
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coverage vs no coverage was employed. The group studied
was a cohort of workers and their adult dependants until all
had reached the age of retirement (65 years) and death
(assumed to be age 85 years). For every dollar spent on a
smoking cessation intervention, it was estimated that
between $5 and $6.50 was saved when considering both
direct and indirect costs. Considering just the money saved
on health care, between $4 and $4.70 was saved per dollar
spent. Over 20 years, the estimated savings for a managed
care organization under this model was between $5.7 and
$6.4 million. This study did estimate the number of cases
of COPD that could be prevented assuming 100 000
employees and 60 000 dependants were affected. At the end
of 20 years, it was expected that 420–670 fewer cases of
obstructive lung disease would be seen.
Two bupropion regimens and 2 behavioral interventions
were combined in another study examining the CE from an
employer’s perspective (Javitz et al 2004b). This trial was
open-label and randomized. The primary measure of success
was self-reported 7-day abstinence after 12 months. An 11%
background quit rate was assumed. The authors concluded
that after 5 years, the employer would be expected to
realize a benefit of $3735 per non-smoker at a total per-
enrollee cost of $119–283 depending on the regimen
used. The per-enrollee benefit to the employer was $472–
832, making the intervention cost-effective. Benefits were
expected to be realized from a decrease in medical
expenses of 19%, a decrease in the number of days absent
from work (4 days for men and 2 days for women prorated
by years post-quit), and a productivity gain of >50%. A
sensitivity analysis did not change the CE outcome. It
should be noted that this study was completed using
Caucasian middle-class subjects who were aware that
bupropion would be given, so these data are likely not
applicable across all patient groups.
Another study examining a program in terms of cost to
the employer using a decision tree analysis found that
combinations of 5 weeks of nicotine replacement treatment
at an average cost of $128, along with 5 clinic visits ($75)
and 5 consultations with a pharmacist ($75) were cost-
effective when patients were fully reimbursed (McGhan and
Smith 1995). The net benefit per converted non-smoker was
found to be $302 for the first year, and $1483 for each
additional year after cessation. The authors of yet another
analysis concluded that an employer could expect a net
benefit of up to $338 per successful quitter in the first year
when bupropion and/or nicotine replacement was provided
(Neilsen and Fiore 2000). The CE of the intervention
remained unaffected after the sensitivity analysis was
completed.
The CE of a program administered by family
physicians in Australia utilizing special training for the
physicians involved demonstrated that the program was
cost-effective for all parties (Buck et al 2000). Physicians
were trained to gauge the readiness of a patient to quit
using the transtheoretical model. Self-reported quit rates
at 12 months were verified with carbon monoxide
readings of <14 ppm. CE was defined as the cost per
quitter believed to have done so as a direct result of the
program. The total program cost to the group of smokers
who were prepared to quit was $23 429, and $25 734 for
the entire group of smokers (1995 dollars). The net quit
rate was 7.7% with associated costs of $421 for the
organizers, $984 for the physicians, $348 for the smokers,
and $1749 for society. Included in the analysis was the
cost of the training which makes this study unique, but
also makes comparisons with other studies difficult. CE
is expected to improve over time as the training is a one
time cost and will continue to be spread over a greater
number of quitters.
A systematic review of the CE of smoking cessation
studies was recently published (Ronckers et al 2005). In
an attempt to standardize the studies for comparison, the
CE ratios were assessed from the standpoint of the
societal perspective. Fourteen studies and 26 overall
comparisons were included, and only studies applicable
to the non-community setting were used. It was
determined that the data analyzing future costs was
lacking as only 3 of the studies reported healthcare
savings, and a single study reported costs anticipated to
be incurred over an expanded lifetime. After
recalculation, most of the intervention costs were more
expensive than originally reported. The mean increase
was more and a double the original estimates. Conversely,
effect size decreased after standardization (7%–94%).
Relapse rates were not controlled for in many studies (12
for short-term, and 18 for long-term). Unaided quit rates
were not incorporated into the data for 16 studies. After
standardization was complete, cost per LYS ranged from
$490 to $15 280 compared with $220 to $5050 for the
original reported data. The incremental CE of counseling
with follow-up compared with counseling alone was
$500–6000. When the included studies were adjusted
with a discount rate, costs nearly doubled. Despite the
disparities between the data pre- and post-standardization,
the interventions all remained cost-effective.International Journal of COPD 2006:1(3) 284
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Cost-effectiveness of relapse
prevention
Dependence on tobacco is a chronic disorder, and relapse is
extremely common (Percival and Milner 2002). It is
estimated that there are 45.7 million former smokers in the
US (Centers for Disease Control and Prevention 1999). The
1994 National Health Interview Supplement provided data
demonstrating that 46.4% of smokers had engaged in a
serious attempt to quit during the previous year (Cinciripini
and McClure 1998). Despite that fact, only 5.7% were able
to quit for a full month or more. The final annual quit rate
was 2.5%. Successful quitters have typically engaged in at
least 3 attempts prior to achieving abstinence, and many
will unfortunately never succeed in achieving continued
abstinence (Curry and McBride 1994; Percival and Milner
2002). The majority of patients who relapse will do so within
7 months of their quit date, and a full 70% will begin using
tobacco again within the year (Ockene et al 2000; Brandon
et al 2004). Those who have engaged in formal treatment
programs are more likely to remain former smokers than
self-quitters who have an estimated 1-year relapse rate of
90%. The risk of relapse, though it does decrease over time,
remains significant even after a year of abstinence. It has
been estimated that over a 7-year period, 50% of
“successful” quitters will begin to smoke again, meaning
that these individuals will not experience the long-term
benefits of cessation (Godfrey et al 2005). Of those patients
that relapse, up to 38% will attempt to quit again within the
following year (Hughes et al 1992). Rates of relapse have
the potential to decrease the overall CE of smoking cessation
interventions. It has been hypothesized that programs aimed
at keeping former smokers from abusing tobacco again may
prove more cost-effective than cessation interventions
themselves (Brandon et al 2004). Follow-up serves to remind
quitters why they stopped smoking in the first place, and
contributes to continuing abstinence (Jackson et al 2001).
A study looking at the effect of a program on
maintenance of smoking abstinence was published in 2004
(Brandon and DeMichele 2004). Mailings and booklets were
mailed out to former smokers in varying combinations and
at different frequencies. Questionnaires were given to
subjects at 12, 18, and 24 months. A 4% discount rate was
employed. For the patients receiving the higher levels of
contact, relapse rates were decreased (p<0.05). Dividing the
mean cost of the two most intensive interventions with the
difference in abstinence rates at 24 months demonstrated
that both were cost effective at $186 and $360 respectively.
The overall cost of each additional abstainer in the study
was $126. It was estimated that a “permanent” quit added
an additional 2.25 QALY to the life of a successful abstainer.
Limitations of this study include the fact that smokers were
only required to have 10 non-smoking weeks behind them
when they enrolled, and the fact that the subjects were self-
selected, meaning that they were probably motivated to
maintain their non-smoking status. Even so, costs compared
with most initial cessation interventions were favorable. The
provision of relapse prevention programs is therefore likely
to be an extremely cost-effective endeavor since repeated
use of cessation programs will in many cases be avoided.
Insurance coverage of smoking
cessation treatments
It has been demonstrated that the elimination of a co-pay
(the amount an insured person is expected to pay out of
pocket for medical services) can increase the rate of program
utilization 3-fold, and that 1.5 times the number of smokers
would quit if full coverage were available (Curry and
McBride 1994). Both the Public Health Service (PHS) and
the Preventive Services Task Force recommend that benefits
for smoking cessation be made available (Department of
Health and Human Services 2005). It is further
recommended that coverage should be available for a
minimum of 2 quit attempts annually, and that co-pays
should be minimal or eliminated completely. Included in
the benefits should be a minimum of 4 counseling sessions
lasting at least 30 minutes, and prescription and over-the-
counter medications (bupropion and nicotine replacement).
The coverage for over the-counter products is especially
important as some may believe that the availability of these
medications to the public somehow relieves the government
and insurers from their obligation to help with financial
support. Cutting out coverage of medications or decreasing
the inventory of medications used in the treatment of
smoking is sometimes done because smoking may be viewed
as a self-inflicted behavioral health problem instead of as a
true chronic addictive disorder with a high risk of relapse
(Jonk et al 2005). Additionally, employers have been
reluctant to pay for cessation aids as employee turnover
negates the certainty that the employer will reap the benefits
of the expenditure directly (Warner et al 1996).
Despite the additional success associated with full
coverage, a survey completed in 2002 found that managed
care organizations (MCOs) cover smoking cessation
sporadically (Warner et al 2004). Approximately 1/3 hadInternational Journal of COPD 2006:1(3) 285
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no set guidelines for the use of such services. It has been
hypothesized that there are several reasons for this lack
of consistency in coverage. First, the MCOs may not be
convinced of the CE of smoking cessation. Second, there
is a limited vocal demand of such services by either
patients or employers. Third, similar to the dilemma that
employers face with turnover, an MCO may not realize
the full benefits of an enrollee transitioning to former-
smoker status as they may not stay with the same plan
(Curry et al 1998). Results generated from the use of a
computer simulation model to assess the effects of an
MCO either covering or not covering smoking cessation
treatment was recently published (Warner et al 2004).
After discounting at the 3% rate, the MCO expenditures
were found to be $20.1 million at a cost per coverage-
induced quitter of $6791, and a cost per LYS of $3417.
It was estimated that over a 30-year period, 19 881
smokers would successfully quit as a direct result of
having coverage through the MCO, and that the average
gain in life-years would be 7.1. By spending money on
cessation the MCO avoids costs related to treatment of
smoking-related disease.
In general, studies have shown that smoking cessation
programs are highly cost effective when compared with
interventions in other areas. It has been estimated that if the
UK’s National Health Service covered the cost of nicotine
patches for quitters, the average cost per LYS would be £392
for those younger than age 55, and £785 for those older
(Stapleton et al 1999). This is less expensive than coverage
for hip replacement, or screening programs for
hyperlipidemia and breast cancer (The Department of Health
1990; Ham 1995). The money spent per benefit user in one
study for which patients had full benefit coverage for
cessation ($328) is also less than that spent on hypertension
treatment ($592) or heart disease ($6941) on an annual basis.
This is especially important considering that treatment in
these cases extends over the life of the patient (Curry et al
1998).
As smoking cessation is more cost-effective than other
interventions which are typically covered by insurance, and
because smoking contributes to a plethora of negative health-
related outcomes that in turn lead to additional health care
expenditures by payers, society, and employers alike, it
seems particularly non-sensical that coverage for complete
cessation programs is not universal. It is a logical conclusion
that spending to help many smokers quit, though increasing
expenditures in the short term, would result in a overall
decrease in spending in multiple areas across the healthcare
continuum. Coverage for smoking cessation should be
universal, and co-pays should be low if not eliminated.
Conclusion
Smoking cessation is the most preventable cause of COPD,
and in fact is the most preventable known cause of death
(Westmaas et al 2000). When examining studies measuring
the CE of interventions, it is difficult to generalize the data.
Populations differ in terms of economics, education, and
motivation, interventions are varied, and the inclusion of
indirect and direct costs is inconsistent. CE will vary in
accordance with whose perspective is used for the study
design. Outcomes are not expressed in a standardized
manner.
What has been consistently demonstrated throughout the
literature, however, is that even modest rates of abstinence
by program users can produce substantial gains in health,
and may therefore prevent significant expenditures in
healthcare over a lifetime. This is especially true when
considering younger smokers who have not yet developed
COPD since smokers who quit by the age of 35 years have
a life-expectancy no different that those who never abused
tobacco (Doll et al 1994).
Healthcare providers are not doing as much as can be
done to help smokers quit. Every year 50%–70% of
smokers visit either a dentist or a physician (Hayward et
al 1989; Anonymous 1993). These practitioners
consistently report low levels of smoking intervention
behaviors (Smith et al 2003). Although brief opportunistic
interventions have the most effect on smokers who use
smaller numbers of cigarettes per day, the interaction is
still important as that light smoker may transition to heavy
smoking over time (West et al 2000). One study found
that a maximum of 3 minutes of anti-smoking advice
could increase quit rates by over 2% (Westmaas et al
2000). Smokers have consistently reported that advice
from healthcare practitioners does help motivate them to
attempt to stop.
Regardless of the methods employed, smoking
cessation remains among the most cost-effective
healthcare interventions. Few interventions in fact have
a lower cost per QALY saved (Godfrey and Fowler 2002).
For this reason, coverage for cessation therapy should
be universal, and programs should be in place for relapse
prevention. Comparing the financial burden that COPD
places on society to the cost per QALY saved certainly
favors this argument.International Journal of COPD 2006:1(3) 286
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